Our Pricing

Comparing Your Mounjaro Treatment Options

Published on: June 03, 2026

When exploring mounjaro treatment options UK patients have, understanding how tirzepatide compares to alternative weight loss medications helps you make an informed choice. At Cured Pharmacy, our UK-registered clinical team provides transparent pricing from £135.00 and expert guidance on whether Mounjaro, Wegovy, Saxenda, or oral alternatives best suit your clinical needs.

How Mounjaro Works: The Dual-Receptor Approach

Mounjaro contains tirzepatide, the first dual GIP/GLP-1 receptor agonist licensed by the MHRA for weight management in the UK [1]. Unlike single-pathway treatments, tirzepatide simultaneously activates glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors, producing enhanced effects on appetite regulation, insulin secretion, and energy expenditure.

In the SURMOUNT-1 trial, adults receiving the 15mg maintenance dose of tirzepatide achieved an average body weight reduction of 22.5% over 72 weeks, compared to 2.4% with placebo [1]. This dual-receptor mechanism explains why clinical outcomes with Mounjaro often exceed those seen with single GLP-1 agonists, though individual responses vary and all treatments require lifestyle modifications alongside medication.

The treatment follows a gradual dose escalation protocol, starting at 2.5mg weekly and increasing every four weeks to minimise gastrointestinal side effects whilst allowing your body to adjust to the medication's metabolic effects [2]. Your UK prescriber will determine the optimal maintenance dose based on your tolerance and weight loss progress during regular clinical reviews.

Mounjaro vs Wegovy: Comparing Injectable GLP-1 Treatments

Both Mounjaro and Wegovy are once-weekly injectable treatments licensed in the UK for chronic weight management, but they differ in their pharmacological mechanisms and clinical trial outcomes. Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro's tirzepatide activates both GIP and GLP-1 receptors [1][3].

Head-to-head trial data from SURPASS-2 demonstrated that tirzepatide produced greater weight reduction than semaglutide 1mg across all dose levels, with the 15mg tirzepatide group achieving approximately 5.5kg more weight loss on average than the semaglutide group over 40 weeks [2]. However, the STEP trials showed semaglutide 2.4mg (Wegovy's dose) achieved an average 14.9% body weight reduction, making it highly effective in its own right [3].

Clinical factors influencing treatment choice include your previous response to GLP-1 medications, tolerance of gastrointestinal side effects, injection frequency preferences, and cost considerations. Both medications require subcutaneous injection once weekly and prescription from a UK-registered prescriber following clinical assessment.

Which Injectable Treatment Suits Your Needs?

Your UK prescriber will assess your BMI, weight loss history, existing medical conditions, current medications, and treatment goals to recommend the most appropriate option. Patients who have previously used liraglutide (Saxenda) or other GLP-1 treatments may be suitable candidates for either medication, whilst those new to injectable weight loss treatments typically start with whichever option best aligns with their clinical profile and budget.

Both treatments are contraindicated in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, and both require regular monitoring by healthcare professionals throughout treatment [2][3].

Saxenda: Daily Injection Alternative to Mounjaro

Saxenda contains liraglutide, an earlier-generation GLP-1 receptor agonist that requires daily subcutaneous injection rather than weekly administration. Whilst this more frequent dosing schedule suits some patients who prefer gradual daily control, others find weekly injections more convenient for long-term adherence.

Clinical trial data showed Saxenda 3mg daily produced an average 8% body weight reduction over 56 weeks in the SCALE Obesity and Prediabetes trial [4]. This represents meaningful weight loss, though typically less than the outcomes observed with newer dual-receptor or higher-dose GLP-1 treatments in their respective trials.

Saxenda may be particularly appropriate for patients who have successfully used daily injectable medications previously, those who prefer more frequent dosing for psychological reassurance, or individuals for whom weekly injectable options are not suitable based on their prescriber's clinical assessment. The medication follows a five-week dose escalation from 0.6mg to the 3mg maintenance dose.

Oral Weight Loss Medications: Orlistat and Mysimba

For patients who prefer oral medications or for whom injectable treatments are unsuitable, Orlistat and Mysimba offer alternative mechanisms for weight management. Orlistat (available as generic formulation, branded Xenical 120mg, or lower-dose Alli 60mg) works by inhibiting pancreatic lipase enzymes, reducing dietary fat absorption by approximately 30% [5].

Orlistat requires three-times-daily dosing with meals containing fat and works best when combined with a reduced-calorie, lower-fat diet. Clinical trials demonstrated an average additional 2.9kg weight loss compared to diet alone over one year [5]. The medication's gastrointestinal side effects, particularly oily stools and faecal urgency, are directly related to dietary fat intake, making adherence to a low-fat eating plan essential.

Mysimba combines naltrexone 8mg and bupropion 90mg in a twice-daily tablet that works through central nervous system pathways affecting appetite and reward centres. The COR-I trial showed an average 6.1% body weight reduction over 56 weeks in patients completing treatment [6]. Mysimba requires gradual dose escalation over four weeks and is contraindicated in patients with uncontrolled hypertension, seizure disorders, or those taking certain antidepressants.

Choosing Between Injectable and Oral Treatments

Injectable GLP-1 and dual-receptor agonists typically produce greater average weight loss in clinical trials compared to oral alternatives, but oral medications suit patients with needle phobia, those preferring tablet-based treatments, or individuals for whom injectable options are medically unsuitable. Your UK prescriber will discuss the benefits and limitations of each approach during your consultation.

All prescription weight loss medications work most effectively when combined with reduced calorie intake and increased physical activity. NICE guidelines emphasise that pharmacological treatment should form part of a comprehensive weight management programme rather than serving as standalone therapy [7].

Understanding Mounjaro Treatment Options UK: Dosing and Titration

Mounjaro's treatment protocol involves careful dose escalation to optimise efficacy whilst minimising side effects. The standard titration schedule begins at 2.5mg weekly for four weeks, increasing to 5mg for four weeks, then 7.5mg, 10mg, 12.5mg, and finally 15mg, with each increment maintained for at least four weeks [2].

Not all patients require the maximum 15mg dose. Your UK prescriber will assess your weight loss response, tolerance of side effects, and clinical goals at each stage to determine whether to continue escalation or maintain your current dose. Some patients achieve their target weight loss at lower maintenance doses, whilst others benefit from progression to higher strengths.

The KwikPen delivery device contains four pre-filled doses and uses a simple once-weekly injection technique into the abdomen, thigh, or upper arm. Proper injection site rotation and technique training from your pharmacist helps minimise injection site reactions and ensures consistent medication absorption throughout treatment.

Cost Considerations and Accessing Treatment Through Cured Pharmacy

At Cured Pharmacy, Mounjaro treatment starts from £124.99 with transparent pricing displayed before you begin your free online consultation. Our UK-registered prescribers complete clinical assessments in under three minutes, reviewing your medical history, current medications, and weight management goals to determine suitability for Mounjaro or alternative treatments.

All medications dispensed by Cured Pharmacy are genuine UK-licensed products sourced through MHRA-approved channels and dispensed under the supervision of our superintendent pharmacist, Tarun Kumar (GPhC 2233073). We provide discreet packaging and reliable delivery, with ongoing support from our clinical team throughout your treatment journey.

Prescription weight loss medications require regular monitoring and review by healthcare professionals. Your prescriber will arrange follow-up assessments to evaluate treatment response, adjust dosing if needed, and ensure the medication remains appropriate and safe for your individual circumstances. Weight loss treatments are most effective when combined with sustainable dietary changes and increased physical activity as part of a comprehensive lifestyle modification programme.

Starting Your Mounjaro Assessment Today

Beginning treatment is straightforward: complete our confidential online consultation form, which a UK-registered prescriber will review to assess your suitability for Mounjaro or recommend alternative options better suited to your clinical profile. If approved, your medication is dispensed by our GPhC-registered pharmacy and dispatched in discreet packaging.

Our clinical team remains available to answer questions about administration technique, managing side effects, or optimising your treatment outcomes. With competitive pricing, genuine UK-licensed medications, and expert pharmaceutical care, Cured Pharmacy supports your weight management journey from initial consultation through to achieving your health goals.

Scientific References

1. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
2. Frías, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
3. Wilding, J. P. H., Batterham, R. L., Calanna, S., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
4. Pi-Sunyer, X., Astrup, A., Fujioka, K., et al. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
5. Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004). XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care, 27(1), 155–161. https://doi.org/10.2337/diacare.27.1.155 [accessed 13 August 2026]
6. Greenway, F. L., Fujioka, K., Plodkowski, R. A., et al. (2010). Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet, 376(9741), 595–605. https://doi.org/10.1016/S0140-6736(10)60888-4 [accessed 13 August 2026]
7. National Institute for Health and Care Excellence. (2023). Obesity: identification, assessment and management (CG189). NICE. https://www.nice.org.uk/guidance/cg189 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment and lifestyle modifications.